NCT03771781已完成不适用
A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Study to Assess the Bioequivalence of Test Formulation With Reference Formulation in Healthy Adult Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration (Cmax)
研究概览
简要总结
Bioequivalence Study of Empagliflozin Tablets and Jardiance® Under Fasting and Fed Conditions in Chinese Healthy Volunteers.
详细描述
A Single-Center,Open-Label,Randomized,Single-Dose,Two-Period,Two-Sequence,Crossover Study to Assess the Bioequivalence of Test Formulation Empagliflozin Tablets with Reference Formulation Jardiance® in Chinese Healthy Adult Subjects under Fasting and Fed Conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female, age 18 to 50 years, inclusive.
- •The body weight of male is not less than 50kg, and female is not less than 45kg. All participants' body mass index (BMI) is between 19~
- •Subjects are fully informed and voluntarily consent to participate in this study.
- •Volunteers can communicate well with researchers and comply with the requirements of this study.
排除标准
- •Any with chronic or active gastrointestinal diseases such as esophageal diseases, gastritis, gastric ulcers, enteritis, active gastrointestinal bleeding or got any digestive tract surgery within three years.
- •Any disease previously or currently suffering from circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, and metabolic abnormalities, and which the researchers believe can interfere with the results of the test.
- •Any history of allergy to drugs, food, or other substances.
- •Dysphagia, difficulty in collecting blood or halo needle, history of dizziness.
- •Those who have undergone surgery during the first four weeks of the trial or are scheduled to perform surgery during the study period.
- •Those who has taken any drug (including vitamin products, Chinese herbs) within 14 days before the study.
- •Those who use any inhibits or induces hepatic metabolism within 30 days before the study.
- •Those who participated in any clinical drug trial within 3 months prior to the trial.
- •Those who donated or lose massive blood within 3 months before the study (> 450 ml).
- •Pregnant and lactating women.
- •Male subjects (or their partners) or female subjects had unprotected sex or pregnancy plans within 2 weeks before screening and 6 months after the end of the trial, Those who are unwilling to use one or more non-drug contraceptive methods (e. G. Complete abstinence, contraceptive ring, partner ligation, etc.) during the study.
- •Drug abusers or those who have used soft drugs for 3 months before the trial or who took hard drugs one year before the study.
- •Those who has special requirements for diet and is unable to follow a uniform diet.
- •Smokers or those who smoked more than 5 cigarettes a day 3 months before the study.
- •An alcoholic or regular drinker for six months before the study, that is, a person who drinks more than 14 units of alcohol a week.
- •People who drink excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250 mL) per day or who do not agree to stop drinking tea, coffee and/or caffeinated beverages during the study period.
- •Those who take drug or food which may affect the drug metabolism(including grapefruit or grapefruit products, dragon fruit, mango, pomelo, orange, yellow purine diet).Or the researchers think that there are other affect drug absorption, distribution, metabolism and excretion of diet.Or refuse to stop eating the diet during the study.
- •Those with abnormal physical examination, electrocardiogram, laboratory examination, vital signs and test related examination with clinical significance .
- •Those who has vital signs with clinical significance, positive urine screening test, positive alcohol breath test or positive female urine pregnancy.
- •Those who has acute illness or concomitant medication occurred before participating in the study.
- •Other reasons which,in the opinion of the medical investigator,would prevent the subject from participating in the study.
研究组 & 干预措施
Empagliflozin Tablets
Other
The test formulation is manufactured by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd.During the study session,subjects will be administered a single does of Empagliflozin Tablets 25mg after fasting and fed conditions.
干预措施: Empagliflozin Tablets (Drug)
Empagliflozin Tab 25 MG
Other
The reference formulation is manufactured by Boehringer Ingelheim International GmbH.During the study session,subjects will be administered a single does of Empagliflozin Tab 25 MG after fasting and fed conditions.
干预措施: Empagliflozin Tab 25 MG (Drug)
结局指标
主要结局
Peak Plasma Concentration (Cmax)
时间窗: 0hours、0.67hours、1hours、1.5hours、2hours、2.5hours、3hours、4hours、6hours、8hours、12hours、24hours、36hours、48hours、72hours
Maximum observed plasma concentration following drug administration from the raw plasma concentration-time data.
次要结局
- Area under the plasma concentration versus time curves (AUC)(0hours、0.67hours、1hours、1.5hours、2hours、2.5hours、3hours、4hours、6hours、8hours、12hours、24hours、36hours、48hours、72hours)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
Unknown
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mgIRCT20200105046010N96???? ????? ?????24
招募中
Unknown
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg..IRCT20200105046010N99Kharazmi Company24
招募中
Unknown
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg tabletIRCT20200623047902N36Actover Co.24
已完成
1 期
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered TogetherHealthyNCT01811953Boehringer Ingelheim48
已完成
1 期
Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mgHealthyNCT00649558Mylan Pharmaceuticals Inc36